CBT is a time-limited, evidence-based psychotherapy that is as efficacious as medication as a sole intervention in anxiety disorders and MDD (4) . As an adjunct to medication, CBT has improved outcomes in schizophrenia (5) and bipolar disorder (4) . Published guidelines, including Canadian ones, recommend CBT as a component of optimal care (6) (7) (8) (9) . Advantages of CBT over pharmacotherapy include fewer dropouts (10) and relapses (11) , higher satisfaction (12) , and fewer side effects. Unlike CBT, medication requires continual administration to maintain effect.
Despite this evidence, CBT is underused internationally. Most Canadians with mental illness do not seek professional help (13) , consistent with findings in other countries (14) . Depression or anxiety patients who do seek help usually consult GPs, who may miss the diagnosis or treat inappropriately (3, 13, 15) . In primary care, individuals with depression receive optimal care only one-half the time (16, 17) , whereas those with anxiety are optimally treated even less frequently (18, 19) . While medication and CBT are both evidence-based treatments for depression and anxiety, medication is used far more often, with 80% to 90% of patients receiving medications alone (16, (20) (21) (22) . In the United States, only 11% of anxiety patients received CBT (20) , and in Great Britain, only 5% to 15% of anxiety patients received counselling of any kind (23) .
Health care policy likely contributes to the underuse of CBT. In Canada, medical visits, medications, and "medically necessary" expenses are covered by the Canada Health Act (24), whereas psychological services are not (3) . Provinces fund psychotherapy administered by physicians, or in the case of nonphysician therapists, those employed by public institutions (3) . Psychotherapy may be covered by private insurance, but most fees are paid for by the individual (25) .
The lack of public funds for effective treatments such as CBT means that optimal care is not accessible to many Canadians. Policy decisions to increase its accessibility, however, will depend on both clinical and economic evidence. Whereas economic evaluations are common and expected for pharmacotherapy, they are rarely conducted for psychological treatments (26) . CEAs consider costs and outcomes of a treatment and its comparator simultaneously (27) . The ICER expresses the extra dollar cost of the intervention over the comparator condition, per additional unit of outcome. Conversely, CCAs result in estimates of total net costs, or affordability, but do not inform questions related to spending efficiency (26, 28) .
The following are the main objectives of this review:
1. To identify and review economic evaluations of the economic impact of CBT alone or in conjunction with other treatments.
2. To elucidate areas for future research to establish the cost-effectiveness of CBT in Canada.
3. To consider the implications of the economic data on Canadian mental health care funding policy.
Methods
We conducted a search of PubMed, EMBASE, and PsycINFO databases (from 1985 to 2005 in English, French, and Spanish), using the key terms cognitive-behavioural therapy, interpersonal therapy, counselling, psychoanalysis, anxiety, obsessive-compulsive disorder, depression, depressive disorder, posttraumatic stress disorder, social phobia, bipolar disorder, personality disorder, eating disorder, psychosis, costs, cost analysis, cost-effectiveness, and economic. We manually searched references of key articles. We retained all studies reporting results of economic analyses of CBT. (29, 31, 36, 38) . Roughly one-half the studies were formal CEAs.
Abbreviations used in this article
Twelve studies evaluated the economic impact of CBT on mood disorders. Six studies of unipolar depression in primary care found that CBT was cost-effective. Patients receiving CBT from a psychologist in addition to TAU by their GP responded better than TAU control subjects, with higher CBT treatment costs offset by less specialized mental health services use (30) . Another RCT comparing CBT or nondirective counselling, with TAU by the GP, found no group differences in clinical response or direct and societal costs at 12 months (36) . In a sample of low-income minority women, pharmacotherapy or CBT was more cost-effective than community referral in the treatment of major depression (32) . A brief CBT program for teens at risk for depression was found to be cost-effective, compared with usual care for prevention (31) .
Training nurses in CBT has also been found to be costeffective. Teaching CBT to home visiting nurses resulted in improved clinical practice and reduced urgent patient contacts in the treatment of postpartum depression, at no increased cost (39) . Another study evaluated a nurse-facilitated CBT self-help for depression or anxiety patients (40) . Compared with TAU, there were no differences in clinical outcomes or mental health care costs for the year following intake-with greater nursing costs in the intervention group offset by lower practice costs.
Two studies evaluated CBT added to medication for psychiatric outpatients. In outpatients with persistent unipolar depression, combined treatment was cost-effective, with a lower relapse rate observed in the CBT group (37) . Similarly, patients with bipolar I disorder receiving CBT had fewer days with bipolar episodes over the next 30 months than did a TAU control group (34) . In both studies, costs of therapy were offset by a reduction in resource use.
A US study examined direct and societal costs of treating unipolar depression with CBT alone, medications alone, or the combination of both (29) . Factored into a cost model was the relative effectiveness of both treatment modalities-with expected rates of relapse, dropout, and partial or complete recovery. CBT was the cheapest, with pharmacotherapy costing 33% more over a 2-year period. Calculations were based on the assumption that both CBT and medications would be administered by the treating psychiatrist. The fact that only a minority of psychiatrists are trained in CBT has obvious practical implications.
In Australia, the Assessing Cost Effectiveness-Mental Health project has published several well-designed studies with data from a nation-wide mental health survey in conjunction with published RCTs and cost estimates to derive populationbased cost-effectiveness models. Reduced disability was the outcome of interest, expressed as DALYs. Three papers evaluated affective disorders, and one calculated current treatment costs over 1 year for all treated patients with MDD, dysthymia, or bipolar affective disorder (16) . Only 55% of these had received an efficacious intervention. Costs of an optimal evidence-based care package, including the use of effective medications or psychological treatments such as CBT, were modelled for this same population. Compared with no treatment, evidence-based care was more cost-effective then current care, reducing the disability burden by 50% at similar cost.
A second study calculated the costs of current treatment compared with evidence-based treatment for all Australian adults consulting for MDD in the year 2000 (44) . Bibliotherapy, group CBT, individual CBT, and TCAs were found to be more cost-effective than current care. SSRIs were the most expensive option. CBT by a public psychologist was more cost-effective than that provided by a private psychologist, highlighting the economic impact of who provides the CBT.
A third Australian study evaluated cost-effectiveness of treatment for children and adolescents with MDD (42) . As for adults, CBT by a public psychologist was the most costeffective intervention; SSRIs as first-line treatment were less cost-effective.
Six health economic studies of CBT for anxiety disorders were identified (10, 11, 14, 33, 43, 45) . A total of 232 primary care patients with PD were randomized to a combined CBT and pharmacology condition or to TAU (33) . The intervention group had more anxiety-free days over the following 12 months, with cost increases well within the acceptable cost-effectiveness range for medical interventions.
Patients with PD attending a specialized psychiatric clinic received CBT or received medication (11) . Calculating direct treatment costs and measuring change in the CGI scale, the authors found CBT to be an especially cost-effective treatment option, regardless of whether patients were on medication at baseline. At 1 year, the gap between CBT and pharmacotherapy widened.
A metaanalysis of PD outcomes compared direct costs of 15 CBT sessions with boosters to medication (10) . At 1 year, the cheapest intervention was imipramine, closely followed by group CBT and individual CBT. Fluoxetine was the most expensive. By 2 years, CBT became even more cost-effective, as a result of the necessity for maintenance of pharmacologic treatment. Moreover, CBT yielded larger, more durable treatment effects and lower attrition rates than did pharmacotherapy. In the sole Canadian study, health care costs were evaluated pre-and post-CBT in individuals with PD with agoraphobia (45) . Compared with the 3-month baseline period, mental health care and overall health care costs were significantly reduced over the year following treatment.
Two papers from the Australian Assessing Cost EffectivenessMental Health project modelled population-based costs of treatment for anxiety disorders. One evaluated the relative cost-effectiveness of optimal compared with current care for PD, SP, GAD, and PTSD over a 1-year treatment period (14) . Compared with current care, the optimal care package (emphasizing CBT as first-line treatment for most people) increased practitioner costs but reduced general health sector costs. For all 4 disorders, optimal care resulted in a 1.5 to 2-fold increase in cost-effectiveness. A second paper looked at the impact of an optimal care package for PD and GAD on direct treatment costs for the population over a 1-year period (43) . CBT by a public psychologist proved to be the most cost-effective intervention for anxiety.
Three UK RCTs investigated the economic impact of adding CBT to TAU for patients with psychotic disorders. Outpatients with persisting psychotic symptoms despite medication were randomized to 2 conditions: 9 months of CBT added to TAU or TAU only (35) . Posttreatment and at 18-month follow-up, the CBT group was considerably improved, whereas little change was noted in the TAU group. Reduced service use offset the extra cost of CBT, making CBT a costequivalent intervention.
Psychosis patients with comorbid substance abuse were randomized to a CBT condition or to TAU (38) . Over 9 months, the CBT group had better outcomes with lower total costs (direct and indirect) than did the TAU group, reflecting fewer hospital days.
A third study randomized patients with acute schizophrenia, admitted to hospital, to CBT or to TAU (41). Total direct costs over the following 2 years were the same for both groups, with reduced resource use offsetting CBT costs. The CBT group enjoyed greater clinical response than did the TAU group, especially for negative symptoms and social functioninggains that were maintained at 2 years.
A tertiary care facility evaluated the cost consequences of an inpatient treatment program featuring CBT for individuals with somatoform disorders (46) . Compared with the 2 years preceding treatment, total costs were significantly lower over the 2 years posttreatment. 
Discussion
Economic data from population modelling, RCTs, and effectiveness studies demonstrate that investment in CBT represents value for dollars spent. As a sole intervention for depression or anxiety, CBT is cheaper than medication. In many care settings, CBT added to UC for depression or treatment-resistant psychosis adds little incremental cost owing to offsets from reduced health care use. Population studies modelling depression and anxiety treatment find that interventions, including CBT, cost less and increase societal benefit, compared with current care.
Greater accessibility of CBT could produce significant cost savings to the Canadian government and contribute to better mental health outcomes. Increased funding for CBT may be difficult to attain: well-defined processes are in place to achieve public health coverage for pharmacotherapies but not for psychological therapies (27) . Universal access for all Canadians to psychotherapy of all kinds, however, is not the goal: psychotherapy is an unregulated field with hundreds of To increase access to CBT, more competent CBT providers (whether psychiatrists, psychologists, nurses, or other therapists) are needed. Students of all mental health disciplines should receive training in CBT. While psychiatry residents are aware of the CBT evidence base and are interested in learning CBT (47) , few Canadian training programs offer exposure adequate for proficiency (48) . This reflects the longstanding predominance of psychoanalytically oriented psychotherapy training in psychiatry-a modality with less demonstrated effectiveness in the treatment of mental disorders (48) . The Royal College has yet to require residency training programs to demonstrate that residents achieve competency in CBT (49), a requirement of US residency programs since 2001 (50).
There is no central Canadian registry of accredited CBT practitioners. Although provincial professional associations typically provide the coordinates of their members to the public, CBT providers are not always identified. Canadawide standards for CBT accreditation should be implemented, reflecting reasonable training parameters to produce competency (50) , perhaps consistent with what is already established in the United States (51) .
Although this review suggests that CBT is cost-effective, there are limitations. First, we did not consider costs of training, restructuring, and recruitment required to increase CBT accessibility. One study reported that savings were so great that CBT start-up costs would not fundamentally alter their cost-effectiveness conclusions (14) .
(Economic analyses of
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Second, the time horizon over which costs and effects were evaluated is only 1 to 2 years. Mental illness often has a chronic or relapsing course. The relative cost-effectiveness of CBT over longer periods might be even greater, given the advantage of CBT over medication in the maintenance of treatment gains and reduced relapse.
Third, cost and outcome variables were narrow in scope. All but 4 studies omitted lost productivity and (or) other societal costs in their analyses, underestimating the economic burden of mental illness. CBT, which is a problem-focused approach to behavioural and cognitive change, may improve productivity more than medication. Most CEAs incorporated outcomes that are difficult for health care decision makers to appreciate: one study derived a cost-effectiveness ratio based on unit change in the CGI (11) . Only 5 studies (14,16,31,43,52) conformed to health economic guidelines by using DALYs or QALYs (27) .
Finally, how generalizable are the results of this review? Only one study reported Canadian data. To establish the costeffectiveness of CBT in Canada, research should focus on the following: costs of current and optimal treatments and the proportion of patients receiving evidence-based care featuring CBT; training and accreditation costs for adequate numbers of CBT practitioners; optimal number and duration of CBT sessions to balance maximum effectiveness at the lowest cost; characteristics of target populations most suitable for CBT; and impact of CBT and comparators on productivity and quality of life.
Economic analyses of CBT in the treatment of mental disorders should inform health care funding policy. The current underuse of CBT, a guideline-endorsed, evidence-based treatment, represents a serious gap in Canadian mental health care. Cost-effectiveness data, where issues of quality of care, quality of life, and cost to society are measured in comparison with other treatments like medication or UC, indicate that CBT is a cost-effective choice with short-and long-term advantages.
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